Relypsa, Inc. Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease  
6/28/2011 9:38:37 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies. The trial, also known as AMETHYST-DN, will evaluate the safety and efficacy of RLY5016 in reducing high potassium levels (hyperkalemia) in patients who have moderate to severe kidney impairment (eGFR < 60 mL/min) and are being treated with renin-angiotensin-aldosterone-system (RAAS) inhibitors, including angiotensin receptor blockers (ARBs).